Literature DB >> 16607285

Hepatocellular carcinoma in Txnip-deficient mice.

S S Sheth1, J S Bodnar, A Ghazalpour, C K Thipphavong, S Tsutsumi, A D Tward, P Demant, T Kodama, H Aburatani, A J Lusis.   

Abstract

The molecular pathogenesis and the genetic aberrations that lead to the progression of hepatocellular carcinoma (HCC) are largely unknown. Here, we demonstrate that the thioredoxin interacting protein (Txnip) gene is a candidate tumor suppressor gene in vivo. We previously showed that the recombinant inbred congenic strain HcB-19 has a spontaneous mutation of the Txnip gene, and we now show that the strain has dramatically increased incidence of HCC, and that the HCC cosegregates with the Txnip mutation. Approximately 40% of the Txnip-deficient mice developed hepatic tumors with an increased prevalence in male mice. Visible tumors develop as early as 8 months of age. Histological analysis confirmed the morphology of HCC in the Txnip-deficient mice. Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of Txnip-deficient mice. The upregulation of p53 preceded tumor development; however, bromodeoxyuridine (BrdU) labeling of normal hepatic tissue of Txnip-deficient mice did not reveal increased cell proliferation. Finally, microarray analyses of tumor, non-tumor adjacent, and normal tissue of Txnip-deficient mice highlighted the genetic differences leading to the predisposition and onset of HCC. Our findings suggest that Txnip deficiency is sufficient to initiate HCC and suggest novel mechanisms in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16607285     DOI: 10.1038/sj.onc.1209394

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

1.  Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors.

Authors:  Marco Ragusa; Luisa Statello; Marco Maugeri; Alessandra Majorana; Davide Barbagallo; Loredana Salito; Mariangela Sammito; Manuela Santonocito; Rosario Angelica; Andrea Cavallaro; Marina Scalia; Rosario Caltabiano; Giuseppe Privitera; Antonio Biondi; Maria Di Vita; Alessandro Cappellani; Enrico Vasquez; Salvatore Lanzafame; Elisabetta Tendi; Salvatore Celeste; Cinzia Di Pietro; Francesco Basile; Michele Purrello
Journal:  J Mol Med (Berl)       Date:  2012-06-04       Impact factor: 4.599

2.  Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.

Authors:  Liangliang Shen; John M O'Shea; Mohan R Kaadige; Stéphanie Cunha; Blake R Wilde; Adam L Cohen; Alana L Welm; Donald E Ayer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas.

Authors:  Vanisri Raviraj; Hui Zhang; Hsin-ya Chien; Louise Cole; Erik W Thompson; Lilian Soon
Journal:  Clin Exp Metastasis       Date:  2012-01-22       Impact factor: 5.150

4.  Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma.

Authors:  James P Hamilton; James J Potter; Lahari Koganti; Stephen J Meltzer; Esteban Mezey
Journal:  Hepatol Res       Date:  2014-03-25       Impact factor: 4.288

5.  E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation.

Authors:  Susanne Knoll; Katharina Fürst; Bhavani Kowtharapu; Ulf Schmitz; Stephan Marquardt; Olaf Wolkenhauer; Hubert Martin; Brigitte M Pützer
Journal:  EMBO Rep       Date:  2014-10-23       Impact factor: 8.807

6.  6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.

Authors:  Yanning Liu; Guohua Lou; John T Norton; Chen Wang; Irawati Kandela; Shuai Tang; Nathaniel I Shank; Pankaj Gupta; Min Huang; Michael J Avram; Richard Green; Andrew Mazar; Daniel Appella; Zhi Chen; Sui Huang
Journal:  FASEB J       Date:  2017-08-17       Impact factor: 5.191

7.  AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1.

Authors:  Ning Wu; Bin Zheng; Adam Shaywitz; Yossi Dagon; Christine Tower; Gary Bellinger; Che-Hung Shen; Jennifer Wen; John Asara; Timothy E McGraw; Barbara B Kahn; Lewis C Cantley
Journal:  Mol Cell       Date:  2013-02-28       Impact factor: 17.970

8.  Rhomboid domain-containing protein 3 is a negative regulator of TLR3-triggered natural killer cell activation.

Authors:  Juan Liu; Shuxun Liu; Meng Xia; Sheng Xu; Chunmei Wang; Yan Bao; Minghong Jiang; Yue Wu; Tian Xu; Xuetao Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

9.  Tandem ChoRE and CCAAT motifs and associated factors regulate Txnip expression in response to glucose or adenosine-containing molecules.

Authors:  Fa-Xing Yu; Yan Luo
Journal:  PLoS One       Date:  2009-12-22       Impact factor: 3.240

10.  Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA.

Authors:  Julia Ling-Yu Chen; Daniel Merl; Christopher W Peterson; Jianli Wu; Patrick Yantyng Liu; Hanwei Yin; Deborah M Muoio; Don E Ayer; Mike West; Jen-Tsan Chi
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.